CellChorus created a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. Photo via Getty Images

A Houston biotech company just announced a new award of $2.5 million.

CellChorus, a spinoff of the Single Cell Lab at the University of Houston, announced the fresh funding, which comes from an SBIR (Small Business Innovation Research) grant from the National Institute of Health (NIH) through its National Center for Advancing Translational Sciences (NCATS).

CellChorus is the business behind a technology called TIMING, which stands for Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. This more in-depth knowledge of immune cells could be instrumental in developing novel therapies in countless disorders, including cancers and infectious diseases.

“While many cell therapies have been approved and are in development, the industry needs an integrated analytical platform that provides a matrix of functional readouts, including cell phenotype and metabolism on the same cells over time,” Rebecca Berdeaux, vice president of science at CellChorus, says in a press release. “We are grateful to NCATS for its support of the development of application-specific kits that apply dynamic, functional single-cell analysis of immune cell phenotype and function. The product we will develop will increase the impact of these therapies to improve the lives of patients.”

A two-year, $2.1 million Phase II grant will begin after the company achieves predetermined milestones under a $350,000 Phase I grant that is currently taking place. As Berdeaux explained, the funds will be used to develop TIMING kits which will manufacture analytics that provide end-users with rapid, specific and predictive results to accelerate translational research and the development and manufacture of more effective cell therapies.

TIMING is more than a great idea whose time has yet to come. It has already been proven in great depth. In fact, last June, CellChorus CEO Daniel Meyer told InnovationMap that he was initially attracted to the technology because it was “very well validated.” At the time, CellChorus had just announced a $2.3 million SBIR Fast-Track grant from the National Institute of General Medical Sciences. The company also went on to win an award in the Life Science category of the 2023 Houston Innovation Awards.

That confirmation of success comes from more than 200 peer-reviewed papers that describe myriad cell types and types of therapy, all of which used data from TIMING assays. TIMING data has benefited industry leaders in everything from research and clinical development to manufacturing. With the new grant, TIMING will become more widely available to scientists making important discoveries relating to the inner workings of the cells that drive our immunity.

Houston's health tech and startup ecosystem has some recent news to catch up on. Photo via Getty Images

Houston health tech startups announce exec, funding — plus more innovation news

SHORT STORIES

Houston startup founders have been moving and shaking in the local innovation ecosystem — from growing their executive boards to raising fresh grant funding.

In this roundup of Houston startup and innovation news, a startup opens a crowdfunding round, a Houston hospital system taps into new technology, and more.

Coya Therapeutics names new president and chief medical officer

Fred Grossman will assume his new role next week. Photo via LinkedIn

Coya Therapeutics Inc. (NASDAQ: COYA), a revolutionary biotech company based in Houston, named Dr. Fred Grossman as president and chief medical officer. The clinical-stage company, which has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again, announced the closing of its $15.25 million IPO in January.

According to the company, Dr. Grossman's position, which was held by Dr. Adrian Hepner, is effective July 17.

“We are grateful for Dr. Hepner’s leadership and excellence in positioning Coya and look forward to having him continue to collaborate with the company in moving our assets forward," Howard H. Berman, CEO of Coya, says in a news release. "We also welcome Dr. Grossman, who brings decades of clinical development experience and successful execution."

Dr. Grossman has held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, Sunovion, Glenmark Pharmaceuticals, and Mesoblast Inc. (NASDAQ: MESO), developing allogeneic cellular therapies for inflammatory diseases.

CellChorus receives another SBIR grant

CellChorus, a biotech startup operating out of the University of Houston Technology Bridge, has secured additional funding. Photo via Getty Images

Fresh off a $2.3 million grant last month, Houston-based CellChorus, a single-cell analysis company, has another grant to celebrate.

The U.S. National Science Foundation has awarded CellChorus a Small Business Innovation Research (SBIR) grant to advance development of its Time-lapse Imaging Microscopy In Nanowell Grids, known as TIMING. The funding will be used to develop novel microscale arrays to support scaling dynamic single-cell analysis.

“This funding will further development of novel arrays to build on the success of our early access laboratory based in Houston,” says Mohsen Fathi, head of technology at CellChorus, in a press release. “This project will support scaling the only platform that can evaluate migration, contact dynamics, killing, survival, subcellular activity, and biomolecule secretion for the same individual cell over time and in high throughput to improve development and delivery of novel therapies.”

According to the release, the company is receiving more than $274,000 as a part of the grant, but CellChorus has the potential of receiving up to $2 million from the second phase.

“This award builds on our recent funding from the National Institute of General Medical Sciences to advance development of a dedicated instrument platform for TIMING,” says Daniel Meyer, CEO of CellChorus, in the release.

Memorial Hermann partners with TMC-backed virtual OB-GYN care

Two Houston-area hospitals now have access to this digital health startup's platform. Photo via Getty Images

The Memorial Hermann Health System has entered into a partnership with Washington, D.C.-based Babyscripts, a virtual care platform for managing obstetrics. The company is backed by the Texas Medical Center's venture fund and has existing ties to the city.

"Memorial Hermann strives to make Greater Houston a place where every woman's pregnancy, delivery and postpartum experience is successful and safe. This innovative partnership is a continuation of that commitment," says Dr. Victoria Regan, vice president of Women's and Children's Services at Memorial Hermann, in a news release.

Now, Memorial Hermann patients will be able to access Babyscripts myJourney, an app that delivers educational content, email campaigns, satisfaction surveys, appointment reminders, and more. The first two hospitals to receive access are Memorial Hermann Memorial City Medical Center and Memorial Hermann The Woodlands Medical Center, with plans to expand the program.

"The ability to access adequate prenatal and postpartum care is one of the largest predictors of maternal and infant health outcomes," says Anish Sebastian, CEO and co-founder of Babyscripts in the release. "With Babyscripts, Memorial Hermann is able to streamline the maternal health experience across their system, adding opportunities for access and providing consistent, high-quality pregnancy care to all patients, regardless of race, income, geography or risk."

Earn Your Freedom launches crowdfunding campaign with Houston nonprofit's support

Earn Your Freedom is looking for financial support from its community. Photo via houston.impacthub.net

Earn Your Freedom, a Houston startup that's gamifying personal finance education, has launched its first crowdfunding campaign in partnership with Impact Hub Houston.

The goal for EYF is to raise $100,000 to support its gaming programs with local schools. Impact Hub Houston is the fiscal sponsor for the raise, which is officially live and open for contributions.

The innovative and interactive web and mobile video game, which officially launched earlier this year to celebrate Financial Literacy Month, was designed to help kids build a strong foundation in money management, economics and investment in a fun and engaging way. It features challenges and real-world scenarios such as renting a first apartment, opening a first bank account, budgeting at the grocery store, buying stocks and index funds and renting or buying real estate.

“We envision a society where financial literacy is accessible to all, and where individuals are enabled with the tools to take control of their financial futures," says Keely McEnery, EYF co-founder and COO, in a press release. "We are bridging the gap between education and application, stepping in before the real-world consequences take place.”

CellChorus, a biotech startup operating out of the University of Houston Technology Bridge, has secured fresh funding. Photo via Getty Images

Houston biotech startup secures $2.3M grant

cha-ching

They say it’s all in the timing. For CellChorus, it’s all in the TIMING. That’s Time-lapse Imaging Microscopy In Nanowell Grids. TIMING is a visual AI program that evaluates cell activation, killing and movement, which allows scientists to better understand how cells function.

The technology is important to the development of novel therapies in the realms of oncology, infectious diseases, and countless other disorders and diseases. By allowing scientists to observe those maladies at their roots, it will enable them to create, and ultimately deliver new medications and other therapies faster, at lower cost, and with a higher success rate.

CellChorus is a spinoff of the Single Cell Lab at the University of Houston. Part of UH’s Technology Bridge, CEO Daniel Meyer connected with co-founder and leader of Single Cell Lab, Navin Varadarajan, through co-founder Laurence Cooper.

“The company had been established, but there were limited operations,” recalls Meyer during a phone call with InnovationMap.

That was the fall of 2020. Now, the team has just announced a $2.3 million SBIR (Small Business Innovation Research) Fast-Track grant from the National Institute of General Medical Sciences.

“This funding will support development of a product offering that builds on the success of our early access laboratory,” Cooper said in a press release. “As the next frontier of cellular analysis, dynamic single-cell analysis will increase the impact that immunotherapies have in improving the lives of patients.”

Meyer is based in the Bay Area, but the rest of the team is in Houston. Meyer has a proven track record as an investor and early stage entrepreneur in life sciences companies, including work as COO of Genospace, which was acquired by HCA Healthcare.

Meyer says that what attracted him to CellChorus was a combination of a clear need for the technology and the fact that it was “very well validated.“

“Developers of immunotherapies need better functional data earlier so that they can develop and deliver better therapies,” he explains.

Another aspect of its appeal was the fact that more than 10 publications featured data from the TIMING platform.

“We’ve had both large and small biopharmas publish data,” says Meyer. “That’s important as well because it shows there’s applicability in both nonprofit and for-profit research.”

Though Meyer himself doesn’t currently live in Houston, he recognizes its importance to CellChorus. He says that it can be difficult for an early stage company to find appropriate lab space, so Technology Bridge was of exceptional importance for CellChorus. Since opening the lab a year and a half ago, Varadarajan and his team have been busy.

“Example projects we have completed include understanding mechanism of action for cell therapy products, selecting lead candidates for T cell engagers, identifying biomarkers of response to cell therapies, and quantifying potency and viability for cell therapy manufacturing technologies,” says Meyer.

And now, CellChorus is collaborating with leaders in the industry.

“These include top-25 biopharmaceutical companies and promising venture-backed biotechnology companies, as well as leading not-for-profit research institutions,” says Meyer in a press release. It’s clear that the TIMING is right for CellChorus to excel.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

5 female-founded Houston startups shine as Innovation Awards finalists

meet the finalists

Houston is home to many standout female founders, making inroads and breakthroughs in every industry.

As part of the 2026 Houston Innovation Awards, our Female-founded Business category honors women-led startups that are shaping Houston innovation.

Five female-founded businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from an AI startup for C-Suite execs to a company developing semi-autonomous crawler robots for corrosion detection.

Read more about these innovative startups and the visionary female founders behind them below. The 2026 winners will be announced on InnovationMap.com in mid-November.

Adair

Artificial intelligence startup Adair uses computational linguistics and behavioral economics to measure, model and quantify the impact of spoken and written language on firm valuation and stock prices. The company works with C-Suite executives of public companies on high-stakes communications before they go live.

The company was founded last year by CEO Kathleen Perley, CPO Alex Duong and CTO Anthony Grivet. It raised $5.6 million earlier this year, according to its application.

ARIX Technologies

Energytech startup ARIX Technologies has developed a semiautonomous VENUS crawler robot to detect corrosion under insulation before it becomes a failure. The robots climb insulated piping in refineries, chemical plants and energy facilities to capture inspection data without removing insulation or building scaffolding. ARIX's inspection portal then turns information from the inspection into data a company can act on.

ARIX was founded in 2017 by Dianna Liu, who serves as director, and Head of Product Petter Wehlin. Craig Malloy serves as CEO. The company has raised more than $22 million in seed funding and a Series A round, according to its application.

Bairitone Health

Healthtech startup Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

FlowCellutions

Energytech startup FlowCellutions is developing a chemistry-agnostic diagnostics platform for flow and metal-air batteries supporting data centers and critical infrastructure. The platform is designed to help reduce operating costs, prevent failures and costly downtime, and extend battery lifetime from approximately seven years to more than 30 years. It has deployed four paid pilots and plans to take insights from the programs to develop its next-gen sensor platform technology.

CEO Becca Segel founded the company in 2022. It is a member of Greentown Labs, and Segel was a 2025 Activate Fellow. The company has raised over $2 million in non-dilutive funding and received a $1.5 million NSF SBIR Fast-Track award earlier this year.

ParaDocs Health

Healthtech startup ParaDocs Health is developing a clinical intelligence platform that helps doctors and care teams streamline administrative tasks and make better use of patient records. Its technology organizes fragmented clinical data into actionable insights, helping care teams identify gaps in care, assess patient risks and simplify documentation and reimbursement.

ParaDocs was founded in 2022 by CEO Dr. Dhini Nasution and CTO Dr. Omar Mohtar. The company participated in the TMCi Biodesign Program and raised a preseed round last year, according to its application.

Rice University launches AI initiative, plans to hire 75 faculty

ai expansion

Houston’s Rice University announced a university-wide artificial intelligence initiative this week that includes hiring 75 new AI-focused faculty. It also shared new details about its planned state-of-the-art facility, The Arc.

Fresh off the announcement of Rice’s new Master of Artificial Intelligence (MAI) coming next fall, the university shared that it plans to expand its AI-related courses and be a “global leader in advanced computing and responsible AI.”

Rice reports that it has already hired 35 faculty members to deepen expertise across schools and departments regarding AI, and plans to recruit 40 more across disciplines including engineering, computing, health, energy, environmental resilience, business, humanities and the arts.

Rice's schools and departments have identified the four cluster areas to guide its hiring:

  • Foundational AI
  • AI for Health
  • AI for Energy, the Environment and Resiliency
  • Responsible AI: Society and Ethics

“Hiring exceptional faculty is essential, but it is only one part of the equation,” Amy Dittmar, Rice’s Howard R. Hughes Provost and executive vice president for academic affairs, said in a news release. “We are building the people, places and partnerships needed to advance AI from foundational discovery to societal impact.”

Another major component of the effort is the planned 200,000-square-foot facility, The Arc, which Rice announced will break ground this fall. Rice will occupy nearly 80,000 square feet of office and laboratory space dedicated to topics including AI, data science, robotics, computational engineering and energy. The university previously announced that The Arc would be completed in Q1 2028.

The Arc will also house the AI Foundry, which is being developed as a collaborative space for industry partners, scientists and students.

“As Rice grows, we are being intentional about where we invest and how we build,” Rice President Reginald DesRoches added in the release. “By bringing together exceptional faculty, a strong interdisciplinary research community, world-class facilities and Houston’s extraordinary innovation ecosystem, Rice has an opportunity not simply to participate in the AI revolution but to help define its future.”